These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27655640)

  • 1. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
    Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
    Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
    BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
    Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
    World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
    Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
    Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
    Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
    PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
    Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
    Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of microRNA expression in serous ovarian carcinoma.
    Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
    Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.
    Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Park HJ; Lee YS; Cho YL
    Cancer Genomics Proteomics; 2017; 14(2):137-141. PubMed ID: 28387653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA expression profiles in serous ovarian carcinoma.
    Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
    Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer.
    Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Lee YS; Cho YL
    Anticancer Res; 2015 May; 35(5):2611-7. PubMed ID: 25964536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma.
    Wang Y; Yan S; Liu X; Zhang W; Li Y; Dong R; Zhang Q; Yang Q; Yuan C; Shen K; Kong B
    Oncol Rep; 2014 Apr; 31(4):1905-10. PubMed ID: 24573236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes virus microRNA expression and significance in serous ovarian cancer.
    Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
    PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
    Yu X; Zhang X; Bi T; Ding Y; Zhao J; Wang C; Jia T; Han D; Guo G; Wang B; Jiang J; Cui S
    Tumour Biol; 2013 Dec; 34(6):3501-8. PubMed ID: 23836287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.
    Hasby EA
    Tumour Biol; 2016 Apr; 37(4):4889-900. PubMed ID: 26526579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.
    Creighton CJ; Fountain MD; Yu Z; Nagaraja AK; Zhu H; Khan M; Olokpa E; Zariff A; Gunaratne PH; Matzuk MM; Anderson ML
    Cancer Res; 2010 Mar; 70(5):1906-15. PubMed ID: 20179198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.
    Yu Z; Kim J; He L; Creighton CJ; Gunaratne PH; Hawkins SM; Matzuk MM
    Biol Reprod; 2014 Nov; 91(5):113. PubMed ID: 25273528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.